Abstract 1398P
Background
Sotorasib after prior IO may increase the risk of immune-related toxicities. We aimed to investigate the potential association between the time interval between prior IO and sotorasib and the incidence of severe hepatotoxicity. IO levels at baseline and on-treatment sotorasib levels were also evaluated.
Methods
Pts with KRAS G12C-mutated NSCLC treated with sotorasib were prospectively enrolled in our biomarker study (NCT05221372). On-treatment ALT/AST was collected. Severe hepatotoxicity was defined as grade ≥3 ALT or AST increase (CTCAE v5.0). Plasma samples were collected for IO and sotorasib concentrations. Sotorasib concentrations were measured by validated liquid chromatography-mass spectrometry to calculate trough concentrations (Ctrough). IO concentrations will be analysed shortly.
Results
At data cut off (April 28th 2023), 90 pts were included, of which 79 (88%) received prior IO. Median time on sotorasib was 107 days (range 28 – 799). The incidence of severe hepatotoxicity was significantly higher in pts with prior IO than those without (29% vs 0%, p=0.04). Pts receiving sotorasib <6 weeks after IO (n=18) had a significantly higher incidence of severe hepatotoxicity than those with intervals of 6-12 weeks (n=24) and ≥12 weeks (n=37) (78% vs 25% vs 8%, respectively, p<0.001) (Table). Sotorasib concentrations of 108 samples from 46 pts were evaluable. Median Ctrough did not differ between those with or without severe hepatotoxicity (90 versus 126 ng/mL, p=0.10). Table: 1398P
No IO (n=11) | Prior IO per interval between last IO and sotorasib (n=79) | ||||
≤6 weeks (n=18) | 6 to 12 weeks (n=24) | ≥12 weeks (n=37) | p-value | ||
Any-grade hepatotoxicity | 7 (64%) | 14 (78%) | 16 (67%) | 8 (22%) | <0.001 |
Grade ≥3 hepatotoxicity | 0 (0%) | 14 (78%) | 6 (25%) | 3 (8%) | <0.001 |
Worst grade | <0.001 | ||||
Grade 1 | 6 (55%) | 0 (0%) | 7 (29%) | 4 (11%) | |
Grade 2 | 1 (9%) | 0 (0%) | 3 (13%) | 1 (3%) | |
Grade 3 | 0 (0%) | 12 (67%) | 5 (21%) | 2 (5%) | |
Grade 4 | 0 (0%) | 2 (11%) | 1 (4%) | 1 (3%) | |
Treatment modification | 0 (0%) | 14 (78%) | 7 (29%) | 3 (8%) | 0.003 |
Interruption and reduction | 0 (0%) | 7 (39%) | 5 (21%) | 2 (5%) | |
Treatment discontinuation | 0 (0%) | 7 (39%) | 2 (8%) | 1 (3%) | |
Days to grade ≥3 hepatotoxicity, median (range) | N/A | 56 (24 – 85) | 49 (25 – 91) | 57 (35 – 65) | 0.975 |
Conclusions
IO followed by sotorasib was associated with severe hepatotoxicity, especially in pts with a short interval between treatments. No association with systemic sotorasib levels was found, further suggesting the influence of prior IO. Relation with baseline IO levels will be presented at the conference. Our results strongly suggest a minimum interval of 6 weeks between last IO course and sotorasib initiation to reduce the risk of hepatotoxicity.
Clinical trial identification
NCT05221372.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.S. Paats: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Bayer, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Takeda. J.G. Aerts: Financial Interests, Personal, Advisory Board: BMS, MSD, Eli Lilly; Financial Interests, Institutional, Advisory Board: AstraZeneca, Pamgene; Financial Interests, Personal, Invited Speaker: AstraZeneca, Eli Lilly, Takeda; Financial Interests, Personal, Other, Inventor/medical advisor: Amphera; Financial Interests, Personal, Stocks/Shares, value is undetermined: Amphera; Financial Interests, Institutional, Royalties, and personal if granted: Amphera; Financial Interests, Institutional, Coordinating PI: Eli Lilly, BMS; Non-Financial Interests, Leadership Role: IASLC. R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer Ingelheim, Novartis; Financial Interests, Institutional, Coordinating PI: Pamgene. A-M.C. Dingemans: Financial Interests, Institutional, Advisory Board: Roche, Sanofi, Amgen, Bayer, Boehringer Ingelheim; Financial Interests, Institutional, Invited Speaker: Takeda, Lilly, Jansen, Pfizer, AstraZeneca; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Local PI: Lilly, Amgen, Daiichi, JNJ, Mirati; Financial Interests, Institutional, Coordinating PI: Roche; Financial Interests, Institutional, Steering Committee Member: Roche; Non-Financial Interests, Other, Chair EORTC lung cancer group: EORTC; Non-Financial Interests, Member: IASCL, ASCO, AACR. All other authors have declared no conflicts of interest.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20